

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07H 21/04, C12P 21/02, C12N 15/11, 15/33, 15/48, 15/85	A1	(11) International Publication Number: WO 98/12207 (43) International Publication Date: 26 March 1998 (26.03.98)
(21) International Application Number: PCT/US97/16639 (22) International Filing Date: 18 September 1997 (18.09.97) (30) Priority Data: 08/717,294 20 September 1996 (20.09.96) US (71) Applicant: THE GENERAL HOSPITAL CORPORATION [US/US]; 55 Fruit Street, Boston, MA 02114 (US). (72) Inventors: SEED, Brian; Apartment 5J, Nine Hawthorne Place, Boston, MA 02114 (US). HAAS, Jorgen; Huberweg 13, D- 69198 Schriesheim (DE). (74) Agent: ELBING, Karen, L.; Clark & Elbing LLP, 176 Federal Street, Boston, MA 02110 (US).	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>	
(54) Title: HIGH LEVEL EXPRESSION OF PROTEINS (57) Abstract The invention features a synthetic gene encoding a protein normally expressed in a mammalian cell wherein at least one non-preferred or less preferred codon in the natural gene encoding the protein has been replaced by a preferred codon encoding the same amino acid.		

	Leu	CTG	118.00	81.21	0.94
	Leu	CTA	3.00	2.06	0.02
	Leu	CTT	1.00	0.69	0.01
5	Leu	CTC	3.00	2.06	0.02
	Pro	CCG	4.00	2.75	0.05
	Pro	CCA	0.00	0.00	0.00
	Pro	CCT	3.00	2.06	0.04
10	Pro	CCC	68.00	46.80	0.91

TABLE 4: Codon Frequency Table of the Native Factor
VIII B Domain Deleted Gene

15	AA	Codon	Number	/1000	Fraction
	Gly	GGG	12.00	8.26	0.15
	Gly	GGA	34.00	23.40	0.41
	Gly	GGT	16.00	11.01	0.20
20	Gly	GGC	20.00	13.76	0.24
	Glu	GAG	33.00	22.71	0.39
	Glu	GAA	51.00	35.10	0.61
	Asp	GAT	55.00	37.85	0.67
25	Asp	GAC	27.00	18.58	0.33
	Val	GTG	29.00	19.96	0.33
	Val	GTA	19.00	13.08	0.22
	Val	GTT	17.00	11.70	0.19
30	Val	GTC	23.00	15.83	0.26
	Ala	GCG	2.00	1.38	0.03
	Ala	GCA	18.00	12.39	0.25
	Ala	GCT	31.00	21.34	0.44
35	Ala	GCC	20.00	13.76	0.28

	Arg	AGG	18.00	12.39	0.25
	Arg	AGA	22.00	15.14	0.30
	Ser	AGT	22.00	15.14	0.18
	Ser	AGC	24.00	16.52	0.20
5					
	Lys	AAG	32.00	22.02	0.40
	Lys	AAA	48.00	33.04	0.60
	Asn	AAT	38.00	26.15	0.60
	Asn	AAC	25.00	17.21	0.40
10					
	Met	ATG	43.00	29.59	1.00
	Ile	ATA	13.00	8.95	0.18
	Ile	ATT	36.00	24.78	0.49
	Ile	ATC	25.00	17.21	0.34
15					
	Thr	ACG	1.00	0.69	0.01
	Thr	ACA	23.00	15.83	0.28
	Thr	ACT	36.00	24.78	0.43
	Thr	ACC	23.00	15.83	0.28
20					
	Trp	TGG	28.00	19.27	1.00
	End	TGA	1.00	0.69	1.00
	Cys	TGT	7.00	4.82	0.37
	Cys	TGC	12.00	8.26	0.63
25					
	End	TAG	0.00	0.00	0.00
	End	TAA	0.00	0.00	0.00
	Tyr	TAT	41.00	28.22	0.60
	Tyr	TAC	27.00	18.58	0.40
30					
	Leu	TTG	20.00	13.76	0.16
	Leu	TTA	10.00	6.88	0.08
	Phe	TTT	45.00	30.97	0.58
	Phe	TTC	32.00	22.02	0.42
35					
	Ser	TCG	2.00	1.38	0.02
	Ser	TCA	27.00	18.58	0.22
	Ser	TCT	27.00	18.58	0.22
	Ser	TCC	18.00	12.39	0.15
40					

	Arg	CGG	6.00	4.13	0.08
	Arg	CGA	10.00	6.88	0.14
	Arg	CGT	7.00	4.82	0.10
	Arg	CGC	10.00	6.88	0.14
5	Gln	CAG	42.00	28.91	0.63
	Gln	CAA	25.00	17.21	0.37
	His	CAT	28.00	19.27	0.55
	His	CAC	23.00	15.83	0.45
10	Leu	CTG	36.00	24.78	0.29
	Leu	CTA	15.00	10.32	0.12
	Leu	CTT	24.00	16.52	0.19
	Leu	CTC	20.00	13.76	0.16
15	Pro	CCG	1.00	0.69	0.01
	Pro	CCA	32.00	22.02	0.43
	Pro	CCT	26.00	17.89	0.35
	Pro	CCC	15.00	10.32	0.20
20					

Use

The synthetic genes of the invention are useful for expressing the a protein normally expressed in mammalian cells in cell culture (e.g. for commercial production of human proteins such as hGH, TPA, Factor VIII, and Factor IX). The synthetic genes of the invention are also useful for gene therapy. For example, a synthetic gene encoding a selected protein can be introduced in to a cell which can express the protein to create a cell which can be administered to a patient in need of the protein. Such cell-based gene therapy techniques are well known to those skilled in the art, see, e.g., Anderson, et al., U.S. Patent No. 5,399,349; Mulligan and Wilson, U.S. Patent No. 5,460,959.

What is claimed is:

1. A synthetic gene encoding a protein normally expressed in an eukaryotic cell wherein at least one non-preferred or less preferred codon in a natural gene encoding said protein has been replaced by a preferred codon encoding the same amino acid, said synthetic gene being capable of expressing
5 said protein at a level which is at least 110% of that expressed by said natural gene in an *in vitro* mammalian cell culture system under identical conditions.

2. The synthetic gene of claim 1 wherein said synthetic gene is capable of expressing said protein at a level which is at least 150% of that expressed by said natural gene in an *in vitro* cell culture system under identical
10 conditions.

3. The synthetic gene of claim 1 wherein said synthetic gene is capable of expressing said protein at a level which is at least 200% of that expressed by said natural gene in an *in vitro* cell culture system under identical conditions.

15 4. The synthetic gene of claim 1 wherein said synthetic gene is capable of expressing said protein at a level which is at least 500% of that expressed by said natural gene in an *in vitro* cell culture system under identical conditions.

5. The synthetic gene of claim 1 wherein said synthetic gene
20 comprises fewer than 5 occurrences of the sequence CG.

6. The synthetic gene of claim 1 wherein at least 10% of the codons in said natural gene are non-preferred codons.

7. The synthetic gene of claim 1 wherein at least 50% of the codons in said natural gene are non-preferred codons.

8. The synthetic gene of claim 1 wherein at least 50% of the non-preferred codons and less preferred codons present in said natural gene have
5 been replaced by preferred codons.

9. The synthetic gene of claim 1 wherein at least 90% of the non-preferred codons and less preferred codons present in said natural gene have been replaced by preferred codons.

10. The synthetic gene of claim 1 wherein said protein is normally
10 expressed by a mammalian cell.

11. The synthetic gene of claim 1 wherein said protein is a retroviral protein.

12. The synthetic gene of claim 1 wherein said protein is a lentiviral protein.

13. The synthetic gene of claim 11 wherein said protein is an HIV
15 protein.

14. The synthetic gene of claim 13 wherein said protein is selected from the group consisting of gag, pol, and env.

15. The synthetic gene of claim 13 wherein said protein is gp120.

16. The synthetic gene of claim 13 wherein said protein is gp160.
17. The synthetic gene of claim 1 wherein said protein is a human protein.
18. The synthetic gene of claim 1 wherein said human protein is
5 Factor VIII.
19. The synthetic gene of claim 1 wherein 20% of the codons are preferred codons.
20. The synthetic gene of claim 18 wherein said gene has the coding sequence present in SEQ ID NO:42.
- 10 21. The synthetic gene of claim 1 wherein said protein is green fluorescent protein.
22. The synthetic gene of claim 20 wherein said synthetic gene is capable of expressing said green fluorescent protein at a level which is at least 200% of that expressed by said natural gene in an *in vitro* mammalian cell
15 culture system under identical conditions.
23. The synthetic gene of claim 20 wherein said synthetic gene is capable of expressing said green fluorescent protein at a level which is at least 1000% of that expressed by said natural gene in an *in vitro* mammalian cell culture system under identical conditions.

24. The synthetic gene of claim 21 having the sequence depicted in Figure 11 (SEQ ID NO:40).

25. An expression vector comprising the synthetic gene of claim 1.

5 26. The expression vector of claim 21, said expression vector being a mammalian expression vector.

27. A mammalian cell harboring with the synthetic gene of claim 1.

28. A method for preparing a synthetic gene encoding a protein
10 normally expressed by mammalian cells, comprising identifying non-preferred and less-preferred codons in the natural gene encoding said protein and replacing one or more of said non-preferred and less-preferred codons with a preferred codon encoding the same amino acid as the replaced codon.

Synp120mn

1/18

1 CTGGAGATCC ATTGTGCTCT AAAGGAGATA CCCGCCAG CACCCTCACC
51 TGGGGTGGCC AGCTGCCCAG GCTGAGGCAA GAGAAGGCCA GAAACCATGC
101 CCATGGGGTC TGTGCAACCG CTGGCCACCT TGTACCTGCT GGGGATGCTG
151 GTCGCTTCCG TGCTAGCCAC CGAGAAGCTG TGGGTGACCG TGTACTACGG
201 CGTGCCCGTG TGAAGGAGG CCACCACCAC CCTGTTCTGC GCCAGCGACG
251 CCAAGGCGTA CGACCCGAG GTGCACAACG TGTGGGCCAC CCAGGCGTGC
301 GTGCCACCG ACCCCAACCC CCAGSAGGTG GAGCTCGTGA ACGTGACCGA
351 GAACTTCAAC ATGTGGAAGA ACAACATGCT GGAGCAGATG CATGAGGACA
401 TCATCAGCCT GTGGGACCAG AGCCTGAAGC CCTGCGTGAA GCTGACCCCC
451 CTGTGCGTGA CCGTGAAGT CACCGACCTG AGGAACACCA CCAACACCAA
501 CAACAGCACC GCAACAACA ACAGCAACAG CGAGGGCACC ATCAAGGGCG
551 GCGAGATGAA CAACTGCAGC TTCAACATCA CCACCAGCAT CCGCGACAAC
601 ATSCAGAAGG ASTACGCCCT GCTGTACAAG CTGGATATCG TGAGCATCGA
651 CAACGACAGC ACCAGCTACC GCCTGATCTC CTGCAACACC AGCGTGATCA
701 CCCAGGCCTG GCCCAAGATC AGCTTCGAGC CCATCCCCAT CCACTACTGC
751 GCGCCCGCCG GCTTCGCCAT CCTGAAGTCC AACGACAAGA AGTTCAGCGG
801 CAAGGGCAGC TGCAAGAACC TGAGCACCGT GCAGTGCACC CACGGCATCC
851 GCGCGGTGGT GAGCACCCAG CTCCTGCTGA ACGGCAGCCT GCGCGAGGAG
901 GAGGTGGTGA TCCGCAGCGA GAACTTCACC GACAACGCCA AGACCATCAT
951 CGTGACCTG AATGAGAGCG TGCAGATCAA CTGCACCGCT CCCAACTACA
1001 ACAAGCGCAA GCGCATCCAC ATCGGCCCCG GCGCGCGCTT CTACACCACC
1051 AAGAACATCA TCGGCACCAT CCGCCAGGCC CACTGCAACA TCTCTAGAGC
1101 CAAGTGGAAC GACACCCTGC GCCAGATCGT GAGCAAGCTG AAGGAGCAGT
1151 TCAAGAACAA GACCATCGTG TTCAACCAGA GCAGCGGCGG CGACCCCGAG
1201 ATCGTGATGC ACAGCTTCAA CTGCGGCGGC GAATTCTTCT ACTGCAACAC
1251 CAGCCCCCTG TTCAACAGCA CCTGGAACGG CAACAACACC TGAACAACA
1301 CCACCGGCAG CAACAACAAT ATTACCCTCC AGTGCAAGAT CAAGCAGATC
1351 ATCAACATGT CGCAGSAGGT GGGCAAGGCC ATGTACGCCC CCCCCATCGA
1401 GCGCCAGATC CGGTGCAGCA GCAACATCAC CGGTCTGCTG CTGACCCCGG
1451 ACGCGGGCAA CGACCCGAC ACCAACGACA CCGAAATCTT CCGCCCCGGC

FIG 1
(SHEET 1 OF 4)

1501 GGGGGCGACA TGC CGGACAA CTGGAGATCT GAGCTGTACA AGTACAAGGT
1551 GGTGACGATC GAGCCCCCTGG GCGTGGCCCC CACCAAGGCC AAGCGCCGCG
1601 TGGTGCAGCG CGAGAAGCGC TAAAGCGGCC GC (SEQ ID NO:34)

FIG 1
(SHEET 2 OF 4)

3/18

Syn gpl60mn

```

1  ACCGAGAAGC TGTGGGTGAC CSTGTACTAC GCGGTGCCCC TGTGGAAGGA
51  GCGCACCAAC ACCCTGTTCT GCGCCAGCGA CGCCAAAGCG TACGACACCG
101 AUGTGACAA CSTGTGCCCC ACCCAGGCGT CCGTGCCCCAC CGACCCCAAC
151 GCGCAGGAGG TGGAGCTCTT GAACGTGACC GAGAACTTCA ACATGTGGAA
201 GAACAACATG CTGGAGCAGA TGCATGAGGA CATCATCAGC CTGTGGGACC
251 AGAGCCTGAA GCGCTGCTTG AAGCTGACCC CCGTGTGCTT GACCCCTCAAC
301 TGGACCGAGC TGAGGAACAC CACCAACACC AACAAACAGCA CCGCCCAAC
351 CAACACCAAC AGCGAGGGCA CCATCAAGGG CGGCCAGATG AAGAAGTCCA
401 GCTTCAACAT CACCAACAGC ATCCCGGACA AGATCCAGAA GGAATACGCC
451 CTGCTGTACA AGCTGGATAT CGTGAGCATC CACAACGACA GCAACAGCTA
501 CCGCCTGATC TCGTCAACA CCGCCTGAT CACCGAGGCC TCGCCCAAGA
551 TCAGCTTCCA GCGCATCCCT ATCCACTACT GCGCCCCCCC CGGCTTCGCC
601 ATCTGAAGT GCAACGACA GAAGTTCAGC GCGAAGGGCA GCTGCAAGAA
651 CGTGACCAAC CTGCAATCCA CCGACGGCAT CCGGCGGGTG GTGAGCAGCC
701 ACCTCTCTCT GAACGGCAGC CTGCGCGAGG AGGAGGTGCT CATCGGCAGC
751 GAGAACTTCA CCGACAACGC CAAGACCATC ATCGTGACCC TGAATGAGAG
801 CGTGCAGATC AACTGCACGC GTCCCAACTA CAACAAGCGC AAGCGCATCC
851 ACATCGGCCC CGGCGCGGCC TTCTACACCA CCAAGAACAT CATCGGCACC
901 ATCCGCGAGC CCGACTGCAA CATCTCTAGA GCGAAGTGGA ACGACACCCT
951 CCGCCAGATC GTGAGCAAGC TGAAGGAGCA GTTCAAGAAC AAGACCATCG
1001 TGTTCACCA GAGCAGCGGC GCGGACCCCG AGATCGTGAT GCACAGCTTC
1051 AACTGCGGCG GCGAATTCTT CTACTGCAAC ACCAGCCCCC TGTTCACAG
1101 CACCTGGAAC GCGAACAACA CCGGAAACA CACCAACGCG ACCAACAACA
1151 ATATTACCCT CCAGTGCAAG ATCAAGCACA TCATCAACAT GTGGCAGGAG
1201 GTGGGCAAGG CCATGTACCC CCGCCCCATC GAGGGCCAGA TCGGTGACG
1251 CAGCAACATC ACCGCTCTGC TCGTGACCCG CGACGCGGCG AAGGACACCG
1301 ACACCAACCA CACCGAAATC TCGCGCCCCG GCGGCGGCGA CATCGCGGAC
1351 AACTCGAGAT CTGAGCTGTA CAAGTACAAG GTGGTGACGA TCGAGCCCCCT
1401 CCGCTGCGCC CCGACCAAGG CCAAGGCGCG CGTGGTGACG CCGGAGAAGC

```

FIG. 1
(SHEET 3 OF 4)

4/18

1451 GGGCCGCCAT CCGCCCCCTG TTCCTGGGCT TCCTGGGGGC GCGGGGCAGC
1501 ACCATGGGGG CCGCCAGCGT GACCCTGACC GTGCAGGCCC GCCTGCTCCT
1551 GAGCGGCATC GTGCAGCAGC AGAACAACTT CCTCCGCGCC ATCGAGGCCC
1601 AGCAGCATAT GTTCCAGCTC ACCGTGTGGG GCATCAAGCA GCTCCAGGCC
1651 CCGGTGCTGG CCGTGGAGCG CTACCTGAAG GACCAGCAGC TCCTGGGCTT
1701 CTGGGGCTGC TCGGGCAAGC TGATCTGCAC CACACCGGTA CCCTGGAACG
1751 CCTCCTGGAG CAACAAGAGC CTGGACGACA TCTGGAACAA CATGACCTGG
1801 ATGCAGTGGG AGCCCGAGAT CGATAACTAC ACCAGCCTGA TCTACAGCCT
1851 GCTGGAGAAG AGCCAGACCC AGCAGGAGAA GAACGAGCAG GAGCTGCTGG
1901 AGCTGGACAA CTGGGCGAGC CTGTGGAAT GGTTCGACAT CACCAACTGG
1951 CTGTGGTACA TCAAAATCTT CATCATGATT GTGGGCGGCC TGGTGGGCTT
2001 CCGCATCGTG TTCGCCGTGC TGAGCATCGT GAACCGCGTG CGCCAGGGCT
2051 ACAGCCCCCT GAGCTCCAG ACCCGGCCCC CCGTGGCCCG CCGGCCCCGAC
2101 CGCCCCGAGG CATCCAGGA GGAGGGCGGC GAGCGCGACC GCGACACCAG
2151 CGGCAGGCTC GTGCAGGCT TCCTGGCGAT CATCTGGGT GACCTCCGCA
2201 GCCTGTTCTT GTTCAGCTAC CACCACCGCG ACCTGCTGCT GATCGCCGCC
2251 CGCATCGTGG AACTCCTAGG CCGCCGCGGC TGGGAGGTGC TGAAGTACTG
2301 GTGGAACCTC CTCCAGTATT GGAGCCAGGA GCTGAAGTCC AGCGCCGTGA
2351 GCCTGCTGAA CGCCACCGCC ATCGCCGTGG CCGAGGGCAC CGACCGCGTG
2401 ATCGAGGTGC TCCAGAGGGC CCGGAGGGCG ATCCTGCACA TCCCCACCCG
2451 CATCCGCCAG CGGCTCGAGA GGCGCTGCT G (SEQ ID NO:35)

FIG. 1
(SHEET 4 OF 4)

5/18




FIGURE 2

6/18




FIGURE 3

7/18




FIGURE 4

8/18




FIGURE 5

9/18

FIGURE 6

10/18




FIGURE 7

11/18




FIGURE 8

12/18




a*b*

FIGURE 9

FIG. 10



14/18

1 GAATTCACGC GTAAGCTTGC CGCCACCATG GTGAGCAAGG GCGAGGAGCT
51 GTTACACGGG GTGGTGCCCA TCCTGGTCGA GCTGGACGGC GACGTGAACG
101 GCCACAAGTT CAGCGTGTCC GGCAGGGGCG AGGGCGATGC CACCTACGGC
151 AAGCTGACCC TGAAGTTCAT CTGCACCACC GGCAAGCTGC CCGTGCCCTG
201 GCCCACCCTC GTGACCACCT TCAGCTACGG CGTGCACTGC TTCAGCCGCT
251 ACCCCGACCA CATGAAGCAG CACGACTTCT TCAAGTCCGC CATGCCCGAA
301 GGCTACGTCC AGGAGCGCAC CATCTTCTTC AAGGACGACG GCAACTACAA
351 GACCCGCGCC GAGGTGAAGT TCGAGGGCGA CACCCTGGTG AACC GCATCG
401 AGCTGAAGGG CATCGACTTC AAGGAGGACG GCAACATCCT GGGGCACAAG
451 CTGGAGTACA ACTACAACAG CCACAACGTC TATATCATGG CCGACAAGCA
501 GAAGAACGGC ATCAAGGTGA ACTTCAAGAT CCGCCACAAC ATCGAGGACG
551 GCAGCGTGCA GCTCGCCGAC CACTACCAGC AGAACACCCC CATCGGCGAC
601 GGCCCCGTGC TGCTGCCCCA CAACCACTAC CTGAGCACCC AGTCCGCCCT
651 GAGCAAAGAC CCCAACGAGA AGCGCGATCA CATGGTCCTG CTGGAGTTCT
701 TGACCGCCGC CGGGATCACT CACGGCATGG ACGAGCTGTA CAAGTAAAGC
751 GGCCGCGGAT CC (SEQ ID NO: 40)

FIG. 11

Native Factor VIII B domain deleted gene segment inserted in the expression vector

```

1   AAGCTTAAAC CATGCCCATG GGGTCTCTGC AACCGCTGGC CACCTTGTA
51  CTGCTGGGGA TGCTGGTGGC TTCCGTGCTA GCCGCCACCA GAAGATACTA
101 CCTGGGTCCA GTGGAACGTG CATGGGACTA TATGCAAAGT GATCTCGGTG
151 AGCTGCCTGT GGACGCAAGA TTTCTCCTA GAGTGCCAAA ATCTTTTCCA
201 TTCAACACCT CAGTCGTGTA CAAAAGACT CTGTTGTAG AATTACGGGA
251 TCACCTTTTC AACATCGCTA AGCCAAGGCC ACCCTGGATG GGTCTGCTAG
301 GTCCTACCAT CCAGGCTGAG GTTTATGATA CAGTGGTCAT TACACTTAAG
351 AACATGGCTT CCCATCCTGT CAGTCTTCAT GCTGTTGGTG TATCCTACTG
401 GAAAGCTTCT GAGGGAGCTG AATATGATGA TCAGACCACT CAAAGGGAGA
451 AAGAAGATGA TAAAGTCTTC CCTGGTGGAA GCCATACATA TGTCTGGCAG
501 GTCCTGAAAG AGAATGGTCC AATGGCCTCT GACCCACTGT GCCTTACCTA
551 CTCATATCTT TCTCATGTGG ACCTGGTAAA AGACTTGAAT TCAGGCCTCA
601 TTGGAGCCCT ACTAGTATGT AGAGAAGGGA GTCTGGCCAA GGAAAAGACA
651 CAGACCTTGC ACAAATTAT ACTACTTTT GCTGTATTTG ATGAAGGGAA
701 AAGTTGGCAC TCAGAAACAA AGAACTCCTT GATGCAGGAT AGGGATGCTG
751 CATCTGCTCG GGCCTGGCCT AAAATGCACA CAGTCAATGG TTATGTAAC
801 AGGTCTCTGC CAGGTCTGAT TGGATGCCAC AGGAAATCAG TCTATTGGCA
851 TGTGATTGGA ATGGGCACCA CTCCTGAAGT GCACTCAATA TTCCTCGAAG
901 GTCACACATT TCTTGTGAGG AACCATCGCC AGGCGTCCTT GGAAATCTCG
951 CCAATAACTT TCCTTACTGC TCAAACACTC TTGATGGACC TTGGACAGTT
1001 TCTACTGTTT TGTATATCT CTTCACCA ACATGATGGC ATGGAAGCTT
1051 ATGTCAAAGT AGACAGCTGT CCAGAGGAAC CCCAACTACG AATGAAAAT
1101 AATGAAGAAG CGGAAGACTA TCATGATGAT CTTACTGATT CTGAAATGGA
1151 TGTGGTCAGG TTTGATGATG ACAACTCTCC TTCCTTTATC CAAATTCGCT
1201 CAGTTGCCAA GAAGCATCCT AAAACTTGGG TACATTACAT TGCTGCTGAA
1251 GAGGAGGACT GGGACTATGC TCCCTTAGTC CTCGCCCCCG ATGACAGAAG
1301 TTATAAAAGT CAATATTGA ACAATGGCCC TCAGCGGATT GGTAGGAAGT
1351 ACAAAAAAGT CCGATTTATG GCATACACAG ATGAAACCTT TAAGACTCGT
1401 GAAGCTATTC AGCATGAATC AGGAATCTTG GGACCTTTAC TTTATGGGGA
1451 AGTTGGAGAC ACACTGTTGA TTATATTTAA GAATCAAGCA AGCAGACCAT
1501 ATAACATCTA CCCTCAGGGA ATCACTGATG TCCGTCCTTT GTATTCAAGG
1551 AGATTACCAA AAGGTGTAAA ACATTTGAAG GATTTTCCAA TTCTGCCAGG
1601 AGAAATATTC AAATATAAAT GGACAGTGAC TGTAGAAGAT GGGCCAACTA
1651 AATCAGATCC TCGGTGCCTG ACCCGCTATT ACTCTAGTTT CGTTAATATG
1701 GAGAGAGATC TAGCTTCAGG ACTCATTGGC CCTCTCCTCA TCTGTACAA
1751 AGAATCTGTA GATCAAAGAG GAAACCAGAT AATGTCAGAC AAGAGGAATG
1801 TCATCCTGTT TTCTGTATTT GATGAGAACC GAAGCTGGTA CCTCAGAG
1851 AATATACAAC GCTTCTCTCC CAATCCAGCT GGAGTGCAGC TTGAGGATCC
1901 AGAGTTCCAA GCCTCCAACA TCATGCACAG CATCAATGGC TATGTTTGTG
1951 ATAGTTTGCA GTTGTCAATT TGTTCGATG AGGTGGCATA CTGGTACATT
2001 CTAAGCATTG GAGCACAGAC TGACTTCCTT TCTGTCTTCT TCTCTGGATA
2051 TACCTTCAA CACAAATGG TCTATGAAGA CACACTCACC CTATTCCCAT
2101 TCTCAGGAGA AACTGTCTTC ATGTCCGATG AAAACCCAGG TCTATGGATT
2151 CTGGGGTGCC ACAACTCAGA CTTTCGGAAC AGAGGCATGA CCGCCTTACT
2201 GAAGGTTTCT AGTTGTGACA AGAACACTGG TGATTATTAC GAGGACAGTT
2251 ATGAAGATAT TTCAGCATA TGGCTGAGTA AAAACAATGC CATTGAACCA
2301 AGAAGCTTCT CCCAGAATTC AAGACACCCT AGCACTAGGC AAAAGCAATT
2351 TAATGCCACC CCACCACTCT TGAAACGCCA TCAACGGGAA ATAACCTGTA
2401 CTACTCTTCA GTCAGATCAA GAGGAAATG ACTATGATGA TACCATATCA
2451 GTTGAAATGA AGAAGGAAGA TTTTGACATT TATGATGAGG ATGAAAATCA
2501 GAGCCCCCGC AGCTTTCAA AGAAAACACG ACACTATTTT ATTGCTGCAG
2551 TGGAGAGGCT CTGGGATTAT GGGATGAGTA GCTCCCCACA TGTCTAAGA
2601 AACAGGGCTC AGAGTGGCAG TGTCCCTCAG TTCAAGAAAC TTGTTTTCCA
2651 GGAATTTACT GATGGCTCCT TTACTCAGCC CTTATACCGT GGAGAACTAA
2701 ATGAACATTT GGGACTCCTG GGGCCATATA TAAGAGCAGA AGTTGAAGAT

```

Fig. 12

(1 of 2)

```
2751 AATATCATGG TAACTTTCAG AAATCAGGCC TCTCGTCCCT ATTCCCTCTA
2801 TTCTAGCCTT ATTTCTTATG AGGAAGATCA GAGGCAAGGA GCAGAACCTA
2851 GAAAAAAGCTT TGTCAAGCCT AATGAAACCA AAACCTACTT TTGGAAGTG
2901 CAACATCATA TGGCACCAC TAAAGATGAG TTTGACTGCA AAGCCTGGGC
2951 TTATTTCTCT GATGTTGACC TGGAAAAAGA TGTGCACTCA GGCCTGATTG
3001 GACCCCTTCT GGTCTGCCAC ACTAACACAC TGAACCTGTC TCATGGGAGA
3051 CAAGTGACAG TACAGGAATT TGCTCTGTTT TTCACCATCT TTGATGAGAC
3101 CAAAAGCTGG TACTTCACTG AAAATATGGA AAGAACTGC AGGGCTCCCT
3151 GCAATATCCA GATGGAAGAT CCCACTTTTA AAGAGAATTA TCGCTCCAT
3201 GCAATCAATG GGTACATAAT GGATACACTA CCTGGCTTAG TAATGGCTCA
3251 GATCAAGG ATTGGATGGT ATCTGCTCAG CATGGGCAGC AATGAAAACA
3301 TCCATTCTAT TCATTTCACT GGACATGTGT TCACTGTACG AAAAAAGAG
3351 GAGTATAAAA TGGCACTGTA CAATCTCTAT CCACGTGTTT TTGAGACAGT
3401 GGAATGTTA CCATCCAAAG CTGGAATTG GCGGGTGGAA TGCCTTATTG
3451 GCGAGCATCT ACATGCTGGG ATGAGCACAC TTTTCTGCT GTACAGCAAT
3501 AAGTGTGAGA TCCCTCTGGG AATGGCTTCT GGACACATTA GAGATTTTCA
3551 GATTACAGCT TCAGGACAAT ATGAGCAGTG GGGCCCAAAG CTGGCCAGAC
3601 TTCATTATTC CGGATCAATC AATGCCCTGA GCACCAAGGA GCCCTTTTCT
3651 TGGATCAAGG TGGATCTGTT GGCACCAATG ATTATTCAG GCATCAAGAC
3701 CCAGGGTGCC CGTCAGAAGT TCTCCAGCCT CTACATCTCT CAGTTTATCA
3751 TCATGTATAG TCTTGATGGG AAGAAGTGGC AGACTTATCG AGGAAATTCC
3801 ACTGGAACCT TAATGGTCTT CTTTGGCAAT GTGGATTCAT CTGGGATAAA
3851 ACACAATATT TTTAACCCTC CAATTATTGC TCGATACATC CGTTGCAAC
3901 CAACCTCATTA TAGCATTCCG AGCACTCTTC CCATGGAGTT CATGGGCTGT
3951 GATTAAATA GTTGAGCAT GCCATTGGGA ATGGAGAGTA AAGCAATATC
4001 AGATGCACAG ATTACTGCTT CATCCTACTT TACCAATATG TTTGCCACCT
4051 GGTCTCCTTC AAAAGCTCGA CTTACCTCC AAGGGAGGAG TAATGCCTGG
4101 AGACCTCAGG TGAATAATCC AAAAGAGTGG CTGCAAGTGG ACTTCCAGAA
4151 GACAATGAAA GTCACAGGAG TAACTACTCA GGGAGTAAAA TCTCTGCTTA
4201 CCAGCATGTA TGTGAAGGAG TTCCTCATCT CCAGCAGTCA AGATGGCCAT
4251 CAGTGGACTC TCTTTTTTCA GAATGGCAAA GTAAACGTTT TCACGGGAAA
4301 TCAAGACTCC TTCACACCTG TGGTGAAGTC TCTAGACCCA CCGTTACTGA
4351 CTCGCTACCT TCGAATTAC CCCCAGAGTT GGGTGCACCA GATTGCCCTG
4401 AGGATGGAGG TTCTGGGCTG CGAGGCACAG GACCTCTACT GAGGGTGGCC
4451 ACTGCAGCAC CTGCCACTGC CGTCACCTCT CCCTCCTCAG CTCCAGGGCA
4501 GTGTCCCTCC CTGGCTTGCC TTCTACCTTT GTGCTAAATC CTAGCAGACA
4551 CTGCCTTGAA GCCTCCTGAA TTAACATCA TCAGTCTGTC ATTCTTTGG
4601 TGGGGGGCCA GGAGGGTGCA TCCAATTAA CTTAACTCTT ACCGTGAGCC
4651 TGCAGGCCCA ACGGGGCCG
```

Fig. 12

(2 of 2)

Synthetic Factor VIII B domain deleted gene segment inserted in the expression vector

```

1  AAGCTTAAAC CATGCCCATG GGGTCTCTGC AACCGCTGGC CACCTTGTAC
51  CTGCTGGGGA TGCTGGTGGC TTCCGTGCTA GCCGCCACCC GCCGCTACTA
101 CCTGGGCGCC GTGGAGCTGT CCTGGGACTA CATGCAGAGC GACCTGGGCG
151 AGCTCCCCGT GGACGCCCGC TCCCCCCCCC GCGTGCCCAA GAGCTTCCCC
201 TTCAACACCA GCGTGGTGTG CAAGAAAACC CTGTTCTGTG AGTTACACCGA
251 CCACCTGTTC AACATTGCCA AGCCGCGCCC CCCCTGGATG GGCCTGTCTG
301 GCCCCACCAT CCAGGCCGAG GTGTACGACA CCGTGGTGAT CACCTTGAAG
351 AACATGGCCA GCCACCCCGT CAGCCTGCAC GCCGTGGGCG TGAGCTACTG
401 GAAGGCCAGC GAGGGCGCCG AGTACGACGA CCAGACGTCC CAGCGCGAGA
451 AGGAGGACGA CAAGGTGTTC CCGGGGGGGA GCCACACCTA CGTGTGGCAG
501 GTGCTTAAGG AGAACGGCCC TATGGCCAGC GACCCCTGTG GCCTGACCTA
551 CAGCTACCTG AGCCACGTGG ACCTGGTGAA GGATCTGAAC AGCGGGCTGA
601 TCGGCGCCCT GCTGGTGTGT CGCGAGGGCA GCCTGCCCAA GGAGAAAACC
651 CAGACCCTGC ACAAGTTCAT CCTGCTGTTC GCCGTGTTCC ACAGGGGGAA
701 GAGCTGGCAC AGCGAGACTA AGAACAGCCT GATGCAGGAC CGCGACGCCG
751 CCAGCGCCCG CGCCTGGCCC AAGATGCACA CCGTTAACGG CTACGTGAAC
801 CGCAGCCTGC CCGGCCTGAT CGGCTGCCAC CGCAAGAGCG TGTA CTGGCA
851 CGTCATCGGC ATGGGCACCA CCCCTGAGGT GCACAGCATC TTCCTGGAGG
901 GCCACACCTT CCTGGTGGCG AACCAACGCC AGGCCAGCCT GGAGATCAGC
951 CCCATCACCT TCCTGACTGC CCAGACCCTG CTGATGGACC TAGGCCAGTT
1001 CCTGCTGTTC TGCCACATCA GCAGCCACCA GCACGACGGC ATGGAGGCTT
1051 ACGTGAAGGT GGACAGCTGC CCGAGGAGC CCCAGCTGCG CATGAAGAAC
1101 AACGAGGAGG CCGAGGACTA CGACGACGAC CTGACCGACA GCGAGATGGA
1151 TGTCGTACCG TTCGACGACG ACAACAGCCC CAGCTTTCAT CAGATCCGCA
1201 GCGTGGCCAA GAAGCACCTT AAGACCTGGG TGCATACAT CGCCGCCGAG
1251 GAGGAGGACT GGGACTACGC CCCGCTAGTA CTGGCCCCCG ACGACCCGAG
1301 CTACAAGAGC CAGTACCTGA ACAACGGCCC CCAGCGCATC GGCCGCAAGT
1351 ACAAGAAGGT GCGCTTCATG GCCTACACCG ACGAGACTTT CAAGACCCGC
1401 GAGGCCATCC AGCAGGAGTC CGGCATCCTC GGGCCCCCTG TGTACGGCGA
1451 GGTGGGCGAC ACCCTGCTGA TCATCTTCAA GAACAGGCC AGCAGGCCCT
1501 ACAACATCTA CCCCCACGGC ATCACCAGCG TGCGCCCCCT GTACAGCCGC
1551 CGCCTGCCCA AGGGCGTGAA GCACCTGAAG GACTTCCCCA TCCTGCCCGG
1601 CGAGATCTTC AAGTACAAGT GGACCGTGAC CGTGGAGGAC GGGCCCCACA
1651 AGACGACCCC CCGCTGCCTG ACCCGCTACT ACAGCAGCTT CGTGAACATG
1701 GAGCGCGACC TGGCCTCCGG ACTGATCGGC CCCCTGCTGA TCTGCTACAA
1751 GGAGAGCGTG GACCAGCGCG GCAACCAGAT CATGAGCGAC AAGCGCAACG
1801 TGATCCTGTT CAGCGTGTTC GACGAGAACC GCAGCTGGTA TCTGACCGAG
1851 AACATCCAGC GCTTCCTGCC CAACCCCGCT GCGGTGCAGC TGAAGATCC
1901 CGAGTTCCAG GCCAGCAACA TCATGCACAG CATCAACGGC TACGTGTTCC
1951 ACAGCCTGCA GCTGAGCGTG TGCCTGCATG AGGTGGCCTA CTGGTACATC
2001 CTGAGCATCG GCGCCAGAC CGACTTCCTG AGCGTGTCTT TCTCCGGGTA
2051 TACCTTCAAG CACAAGATGG TGTACGAGGA CACCCTGACC CTGTTCCCTT
2101 TCTCGGGCGA GACTGTGTTC ATGTCTATGG AGAACCCCGG CCTGTGGATT
2151 CTGGGCTGCC ACAACAGCGA CTTCCGCAAC CGCGGCATGA CTGCCCTGCT
2201 GAAAGTCTCC AGCTGCGACA AGAACACCGC CGACTACTAC GAGGACAGCT
2251 ACGAGGACAT CTCCGCCTAC CTGCTGTCCA AGAACACCGC CATCGAGCCC
2301 CGTCCCTTCT CCAAAACTC CCGCCACCCC AGCACCGGTC AGAAGCAGTT
2351 CAACGCCACC CCCCCGTGC TGAAGCGCCA CCAGCGCGAG ATCACCAGCA
2401 CCACCTGCA AAGCGACCAG GAGGAGATCG ACTACGACGA CACCATCAGC
2451 GTGGAGATGA AGAAGGAGGA CTTGACATC TACGACGAGG ACGAGAACCA
2501 GAGCCCCCGC TCCTTCCAAA AGAAAACCCG CCACTACTTC ATCGCCGCGC
2551 TGGAGCGCCT GTGGGACTAC GGCATGAGCA GCAGCCCCCA CGTCTGGCG
2601 AACCGCGCCC AGAGCGGCGC CGTCCCCCAG TTCAAGAGG TGGTGTCCA
2651 GGAGTTCACC GACGCGAGCT TCACCCAGCC CCTGTACCGC GCGGAGCTGA
2701 ACGAGCACCT GGGCCTGCTC GGGCCCTACA TCCGCGCCGA GGTGAGGAC

```

Fig. 13

(1 of 2)

2751 AACATCATGG TGACCTTCCG CAACCAAGCC TCCCGGCCCT ACTCCTTCTA
2801 CTCCTCCCTG ATCAGCTACG AGGAGGACCA GCGCCAGGGC GCCGAGCCCC
2851 GCAAGAACTT CGTGAAGCCC AACGAGACTA AGACCTACTT CTGGAAGGTG
2901 CAGCACCACA TGGCCCCCAC CAAGGACGAG TCGACTGCA AGGCCTGGGC
2951 CTAATTACAG GACGTGGACC TGGAGAAGGA CCTGCACAGC GGCCTGATCG
3001 GCCCCCTGCT GGTGTGCCAC ACCAACACCC TGAACCCCCC CCACGGGAGG
3051 CAGGTGACTG TGCAGGAATT TGCCTGTTC TTCACCATCT TCGACGAGAC
3101 TAAGAGCTGG TACTTCACCG AGAACATGGA GCGCAACTGC CGCGCCCCCT
3151 GCAACATCCA GATGGAAGAT CCCACCTTCA AGGAGAACTA CCGCTTCCAC
3201 GCCATCAACG GCTACATCAT GGACACCCTG CCGGCCCTGG TGATGGCCCA
3251 GGACCAGCGC ATCCGCTGGT ACCTGCTGTC TATGGGCAGC AACGAGAACA
3301 TCCACAGCAT CCACTTCAGC GGCCACGTTT TCACCGTGGC CAAGAAGGAG
3351 GAGTACAAGA TGGCCCTGTA CAACCTGTAC CCGGGCGTGT TCGAGACTGT
3401 GGAGATGCTG CCCAGCAAGG CCGGGATCTG GCGCGTGGAG TGCCTGATCG
3451 GCGAGCACCT GCACGCCGCC ATGAGCACCC TGTTCTTGGT GTACAGCAAC
3501 AAGTGCCAGA CCCCCCTGGG CATGGCCAGC GGCCACATCC CGCACTTCCA
3551 GATCACCGCC AGCGGCCAOT ACGGCCAGTG GGCTCCCAAG CTGGCCCGCC
3601 TGCACTACAG CCGCAGCATC AACGCCTGGT CGACCAAGGA GCCCTTCTCC
3651 TGGATCAAGG TGGACCTGCT GGCCCCCATG ATCATCCAG GCATCAAGAC
3701 CCAGGGCGCC CGCCAGAAGT TCAGCAGCCT GTACATCAGC CAGTTCATCA
3751 TCATGTACTC TCTAGACGGC AAGAAGTGGC AGACCTACCG CGGCAACAGC
3801 ACCGGCACCC TGATGGTGT CTTCGGCAAC GTGGACAGCA CGGCATCAA
3851 GCACAACATC TTCAACCCCC CCATCATCGC CCGCTACATC CGCCTGCACC
3901 CCACCCACTA CAGCATCCGC AGCACCCCTG GCATGGAGCT GATGGGCTGC
3951 GACCTGAACA GCTGCAGCAT GCCCCCTGGC ATGGAGAGCA AGGCCATCAG
4001 CGACGCCCAG ATCACCGCCT CCAGCTACTT CACCAACATG TTCGCCACCT
4051 GGAGCCCCAG CAAGGCCCGC CTGCACCTGC AGGGCCGCAG CAACGCCCTG
4101 CGCCCCCAGG TGAACAACCC CAAGGAGTGG CTGCAGGTGG ACTTCCAGAA
4151 AACCATGAAG GTGACTGGCG TGACCACCCA GGGCGTCAAG AGCCTGCTGA
4201 CCAGCATGTA CGTGAAGGAG TTCCTGATCA GCAGCAGCCA GGACGGCCAC
4251 CAGTGGACCC TGTTCCTCCA AAACGGCAAG GTGAAGGTGT TCCAGGGCAA
4301 CCAGGACAGC TTCACACCGG TCGTGAACAG CCTGGACCCC CCCCTGCTGA
4351 CCCGCTACCT GCGCATCCAC CCCCAGAGCT GGGTGCACCA GATCGCCCTG
4401 CCGATGGAGG TGCTGGGCTG CGAGCCCCAG CACCTGTACT GAAGCGGCCG
4451 C

Fig. 13

(2 of 2)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/16639

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C07H 21/04; C12P 21/02; C12N 15/11, 15/33, 15/48, 15/85

US CL : 435/69.1, 70.1, 70.3, 172.3, 320.1; 536/23.1, 23.72, 25.3

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/69.1, 70.1, 70.3, 172.3, 320.1; 536/23.1, 23.72, 25.3

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

BIOSIS, EMBASE, MEDLINE, DERWENT

search terms: gene?, dna?, nucleic acid?, deoxyribonucleic?, synthe?, prefer? non-prefer? codon?

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96/09378 A (THE GENERAL HOSPITAL CORPORATION) 28 March 1996, abstract, page 1, line 20-page 4, line 26, page 15, lines 25-32, page 17, lines 27-39 and pages 42-54.	1-28
A	SEETHARAM et al. Mistranslation in IGF-1 During Over- Expression of the Protein in Escherichia coli Using a Synthetic Gene Containing Low Frequency Codons. Biochem. Biophys. Res. Comm. 30 August 1988. Vol. 155. No. 1. entire document.	1-28

☐ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A*	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

21 NOVEMBER 1997

Date of mailing of the international search report

22 DEC 1997

 Name and mailing address of the ISA/US
 Commissioner of Patents and Trademarks
 Box PCT
 Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

NANCY J. DEGEN

Telephone No. (703) 308-0196